Compare Repligen Corporation Common Stock (RGEN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while iShares 0 3 Month Treasury Bond ETF trades at $100.55 (market cap $115.19B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 10.3× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and iShares 0 3 Month Treasury Bond ETF for 51 Days on average.
| RGEN | SGOV | |
|---|---|---|
Market Cap | $11.14B | $115.19B |
Volume | 1,259,263 | 18,240,700 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $100.72 |
52-Week Low | $102.87 | $100.28 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52 with no price change. The technical outlook is bearish, driven by moving averages, while oscillators are neutral. Recent corporate actions include scheduled dividend payments through late 2026. Market sentiment is influenced by a significant bond selloff and rising Treasury yields, with institutional activity showing a reduction in holdings by Envestnet Asset Management.
The outlook for SGOV is cautious amid a challenging bond market environment. Investment opportunities lie in its short-duration Treasury exposure during rate volatility, but risks include prolonged high interest rates and inflation pressures. Investors should weigh the ETF's stability against macroeconomic headwinds impacting fixed income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
